EFPIA and its members are conscious of the importance of providing accurate, fair and objective information about medicinal products so that rational decisions can be made as to their use. With this in mind, EFPIA has adopted the EFPIA HCP Code on the Promotion of Prescription-Only Medicines to, and Interactions with, Healthcare Professionals (the “EFPIA HCP Code”). The EFPIA HCP Code reflects the requirements of Council Directive 2001/83/EC, as amended, relating to medicinal products for human use (the “Directive”). The EFPIA HCP Code fits into the general framework established by the Directive, which recognises the role of voluntary control of advertising of medicinal products by self-regulatory bodies and recourse to such bodies when complaints arise.
EFPIA encourages competition among pharmaceutical companies. The EFPIA HCP Code is not intended to restrain the promotion of medicinal products to, or limit interactions with, healthcare professionals in a manner that is detrimental to fair competition. Instead, it seeks to ensure that pharmaceutical companies conduct such promotion and interaction in a truthful manner, avoiding deceptive practices and potential conflicts of interest with healthcare professionals, and in compliance with applicable laws and regulations.
The EFPIA HCP Code thereby aims to foster an environment where the general public can be confident that choices regarding their medicines are being made on the basis of the merits of each product and the healthcare needs of patients.
The EFPIA HCP Code covers the promotion to healthcare professionals of prescriptiononly medicinal products and interactions between healthcare professionals and pharmaceutical companies. The EFPIA HCP Code is applicable to EFPIA member companies, their subsidiaries, and any companies affiliated with EFPIA member companies or their subsidiaries if such affiliated companies have agreed to be bound by the EFPIA HCP Code (“Member Companies”).